SITE SPECIFIC DATA ITEMS (SSDI)/ GRADE

Description

High Risk Cytogenetics is defined as one or more of t(4;14), t(14;16), or del 17p identified from FISH test results and is part of the staging criteria for plasma cell myeloma. The Revised International Staging System (RISS or R-ISS) is now used to stage plasma cell myeloma (9732/3), using several different criteria. The stages are based on the absence or presence of the following related criteria. * 3931: Serum Beta-2 Microglobulin Pretreatment Level * 3930: Serum Albumin Pretreatment Level * 3857: High Risk Cytogenetics * 3869: LDH Level Required for Staging: The AJCC Staging System Plasma Cell Myeloma and Plasma Cell Disorders (9732/3 only) and EOD. * Note: RISS stage is not applicable for the descriptions of plasma multiple myeloma that are listed in the codes 1 and 9 in the SSDI Schema Discriminator 1: Plasma Cell Myeloma Terminology. If you have coded 1 or 9 for this Schema Discriminator, the four data items listed above are BLANK. The RISS stages are * Stage I: Serum Beta-2-microglobulin <3.5 mg/L and serum albumin > 3.5 g/dL and no high-risk cytogenetics and Normal LDH * Stage II: Not R-ISS I or III * Stage III: Serum Beta-2-microglobulin > 5.5 mg/L and high-risk cytogenetics and/or high LDH

Notes

**Note:** **Physician statement** * Physician statement of presence or absence of high-risk cytogenetics can be used to code this data item when no other information is available * Record this data item based on physician statement or FISH test interpretation performed at diagnosis (pre-treatment). * If the presence/absence of high-risk cytogenetics determined by available test results differs from the physician statement of presence/absence, the physician's statement takes precedence.